1
Clinical Trials associated with Murine CART19(University of Pennsylvania)CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D).
100 Clinical Results associated with Murine CART19(University of Pennsylvania)
100 Translational Medicine associated with Murine CART19(University of Pennsylvania)
100 Patents (Medical) associated with Murine CART19(University of Pennsylvania)
100 Deals associated with Murine CART19(University of Pennsylvania)